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（２ 群馬大院・医・病態病理学）
【背 景】 近年我々は,グリオーマがIDH･TERT promoter
領域の遺伝子変異および染色体1p19q共欠失の有無に基
づき,分子遺伝学的に5つのグループ (Triple-Positive,
IDH Mutation Only,TERT Mutation Only,TERT and IDH Mutation,Triple-Negative)に分類されることを報告
した.この検討さらに発展させ,50の遺伝子変異とコピー
数異常の解析によって各グループ間の特徴的な異常を詳細




【結 果】 148例は,Triple-Positive 34例 (23％),IDH Mutation Only 40例 (27％),TERT Mutation Only 64例
(44％),TERT and IDH Mutation 6例 (4％),Triple-











22．Evaluation of Diffusion Weighted MR Imaging and
??F FDG PET for Monitoring Triple Negative Breast Cancer Response to Cisplatin Treatment Nguyen Thu Huong,Hirofumi Hanaoka,
Takahito Nakajima and Yoshito Tsushima
（Department of Diagnostic Radiology and Nuclear Medicine,Gunma University Gradu-
ate School of Medicine）
【Background】 The utility of platinum agents for triple negative breast cancer(TNBC)therapy is controversial since sometimes Cisplatin resistance occurs.In this study,
we planned to evaluate the usefulness of??F-FDG PET and difusion weighted MR imaging(DWI)as the early predic-
tor for Cisplatin treatment.【Methods】 Cisplatin was intraperitonealy injected into TNBC tumor bearing mice.
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Smal animal PET and animal MRI scanner were used for image acquiring on before treatment(day 0),day 3,and day 7 after treatment.The highest standardized uptake value
(SUVmax)and the average of apparent difusion coeficient value(ADCmean)were measured.Tumor size was fol-
owed up until it reached to 2000 mm?.【Results】 We divided mice into two groups(response and non response)
based on tumor size(threshold of tumor size on day 14:250 mm?).SUVmax in response vs.non response group on day 0 and day 3 were not significant diference,while SUVmax on day 7 in response group was significantly lower than those of non response group(0.68±0.08 vs.1.31±0.19,
respectively,P＝0.001).ADCmean(mm?/s)in response vs.
non response group on day 0 and day 3 were 0.30±0.24 vs.
0.53±0.32,0.42±0.17 vs.0.38±0.25,respectively.There were no significant diference of ADCmean between two groups on day 0 and day 3,but ADCmean had tended to rise in response group on day 3.【Conclusions】 SUV-
max change may be an early predictor to determine the response of triple negative breast cancer to Cisplatin treat-
ment.Since number of mice would be not enough,we need further studies.
23．?Y-Bevacizumab Radioimmunotherapy(RIT)in Breast Cancer Xenograft:A Preliminary Study Ryan Yudistiro,Ayako Takahashi and Yoshito Tsushima
（Department of Diagnostic Radiology and Nuclear Medicine,Gunma University Gradu-
ate School of Medicine）
Vascular endothelial growth factor(VEGF)is an endoth-
elial cel-specific mitogen that play important roles in tumor angiogenesis.VEGF is overexpressed in several cancer cels including breast cancer cels.Bevacizumab is a monoclonal antibody that binds and inactivates VEGF to inhibit tumor angiogenesis,growth,and proliferation.Bevacizumab has succeeded in labeling with several radioisotopes and has potential for specificaly targeted radioimmunotherapy
(RIT).We evaluated in vivo therapeutic study of Bevac-
izumab that radiolabeled with??Y as RIT in breast cancer xenograft. Bevacizumab was conjugated with dieth-
ylenetriaminepentaacetic acid(DTPA)and labeled with radioisotopes.In vivo biodistribution and therapeutic study was performed by using???In-DTPA-bevacizumab and
??Y-DTPA-bevacizumab on mice bearing MDA-MB-231 breast cancer cel line.From 72 hours biodistribution study,
???In-DTPA-bevacizumab showed high specific tumor up-
take and significantly higher than???In-labeled non-specific monoclonal antibody(18.10±2.01％dose/gram and 6.44±
0.71％dose/gram,respectively,p?0.001).From preliminary therapeutic study,??Y-DTPA-bevacizumab treated mice showed slower tumor growth than control mice(tumor volume at 10 days after treatment:374.0 and 583.1 mm?(n＝
2),and 901.2±445.6 mm?(n＝3),respectively).Based on these results,??Y-DTPA-bevacizumab RIT can be a poten-
tial targeted RIT in breast cancer.
24．Detection of EGFR Positive Lung Squamous Cel Carcinoma by Dynamic Fluorescence Imaging Xieyi Zhang,Mai Kim,Aiko Yamaguchi,
Takahito Nakajima and Yoshito Tsushima
（Department of Diagnostic Radiology and Nuclear Medicine,Gunma University Gradu-
ate School of Medicine）
【Objective】 To test the possibility by using fluorescence imaging to diferentiate between epidermal growth factor receptor(EGFR)-expressing and non-expressing lung squamous cel carcinoma(SCC).【Materials and methods】 Lung SCC EGFR-expression cel line H226 and non-expression cel line H520 were used.Panitumumab targeting EGFR conjugated to indocyanine green(ICG)was used for fluores-
cence imaging. Fluorescent microscopy study and flow cytometry were performed to test the ability of in vitro binding.2 milion H520 or H226 were subcutaneously injected into two sides of dorsal in the mice.1 week after implantation,50μg Panitumumab-ICG was injected intravenously and fluorescence images were acquired 6,24,
48 and 72 hours after injection. The ratios of average fluorescent signal(AFS)of tumors and background were calculated for analysis and comparison.【Results】
Panitumumab-ICG were initialy quenched and showed an increased fluorescence signal.Fluorescent microscopy study and flow cytometry showed specific binding between conju-
gate and H226 but no specific binding with H520.The ratios of AFS at 48 hours(2.17±0.45 versus 0.68±0.16)and 72 hours(2.82±0.66 versus 0.44±0.21)showed significant diferences between H226 and H520(p＜0.05).However,
there was no significant diference of the ratio between 48-
hour and 72-hour images in H226 tumors(p＝0.135).
【Conclusion】 Panitumumab-ICG demonstrated a promise as a method to diferentiate EGFR positive and negative lung SCC.The optimal time to acquire such fluorescent imaging was 48 hours after conjugate injection.In vivo fluorescence study by using lung SCC lymph node metas-
tasis tumor model wil be performed for next step.
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